Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.
Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Dyne Therapeutics to Present at Upcoming Investor Conferences